Northstar Advisory Group LLC Has $217,000 Holdings in Stryker Co. (NYSE:SYK)

Northstar Advisory Group LLC lessened its stake in Stryker Co. (NYSE:SYK) by 49.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 724 shares of the medical technology company’s stock after selling 702 shares during the quarter. Northstar Advisory Group LLC’s holdings in Stryker were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Freedom Wealth Alliance LLC acquired a new position in Stryker during the fourth quarter worth about $26,000. Quarry LP acquired a new position in shares of Stryker in the first quarter valued at approximately $27,000. Rise Advisors LLC increased its stake in shares of Stryker by 692.9% in the third quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock valued at $30,000 after buying an additional 97 shares during the period. West Tower Group LLC acquired a new position in shares of Stryker in the second quarter valued at approximately $35,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of Stryker in the second quarter valued at approximately $38,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Truist Financial upped their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Roth Mkm increased their target price on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and increased their target price for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Morgan Stanley increased their target price on shares of Stryker from $300.00 to $320.00 and gave the company an “equal weight” rating in a research report on Monday, December 4th. Finally, Wells Fargo & Company increased their price target on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $331.52.

Insider Activity

In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. Over the last three months, insiders have sold 212,109 shares of company stock valued at $72,845,768. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $355.81 on Thursday. The company has a market cap of $135.19 billion, a PE ratio of 43.52, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $342.51 and a 200-day moving average price of $305.23. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.00 EPS. As a group, equities analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.90%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.